Albany, NY -- (SBWIRE) -- 12/04/2014 -- In the coming years, the market for anti-migraine drugs is anticipated to witness several launches of new generic migraine drugs that will steadily increase the drug-treatment levels and rate of diagnosis paving a sustainable path to an annual global growth of the overall anti-migraine drugs market.

View Full Report
http://www.marketresearchreports.biz/analysis/207524

Migraines are frequent attacks of moderate to severe headaches and anti-migraine drugs are its therapeutic curing agents. In the next five years, the cost of migraine drugs is expected to reduce due to the growing awareness of migraine and its treatment via specific anti-migraine drugs amongst individuals in the emerging countries.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/207524

The market for anti-migraine drugs is projected for an upward growth curve mainly due to the development of new generic entrants and treatment therapies such as BOTOX and calcitonin gene-related peptides (CGRP) receptor antagonist. The market is also poised for a significant growth due to increasing incidences of migraine sufferers, increased acceptance levels, and technological advances in the development of anti-migraine drugs, thus boosting the demand for anti-migraine drugs market to grow further on a global level.

Some of the major anti-migraine drugs used to cure migraine problems include, Triptans like Sumatriptan, Zolmitriptan, and others. 

The United States is accounted to be the largest market for anti-migraine drugs as stated by a Medline article earlier. Around 12% of the U.S. population suffers from migraine headaches, which precisely pushes a number of drug companies to manufacture specific preventive medications and anti-migraine drugs that help patients relieve their intense and periodic headaches with the right treatment.

Explore All Latest Published Reports By Daedal Research
http://www.marketresearchreports.biz/publisher/102

The key market players majorly contributing to the anti-migraine drugs market include GlaxoSmithKline plc, Abbott Laboratories, Inc., Pfizer Inc., Impax, Endo Pharmaceuticals, Eli Lilly and Company, Eisai, Inc., Nautilus and Allergan, and AstraZeneca plc.

The market research reports provided by Marketresearchreports.biz based on the anti-migraine drugs market also include a comprehensive review of micro and macro factors necessary for the existing players and new entrants, as well as covers a complete market study of recent developments in the anti-migraine drugs market.

Related Reports

Pharmaceutical Business Confidence Report Q4 2014

View Full Report
http://www.marketresearchreports.biz/analysis/234803

Pharmaceutical Business Confidence Report Q4 2014" is a new report by Kable that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the pharmaceutical industry over October-December 2014. This report also examines executive opinions with regards to the current and future state of the economy and its effect on the industry.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/234803

It analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry. Furthermore, this report provides an overview of the key priorities, threats, and opportunities for the global pharmaceutical industry. In addition, the report includes the forecasts of the projected investments on pharmaceutical equipment, procurement budget allocations and the leading suppliers of pharmaceutical equipment in the pharmaceutical industry.

Beta Pharma, Inc. - Product Pipeline Review - 2014

View Full Report
http://www.marketresearchreports.biz/analysis/234496

Global Markets Directs, Beta Pharma, Inc. - Product Pipeline Review - 2014, provides an overview of the Beta Pharma, Inc.s pharmaceutical research and development focus.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/234496

This report provides comprehensive information on the current therapeutic developmental pipeline of Beta Pharma, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

About MarketResearchReports.biz
Marketresearchreports.biz is the most comprehensive collection of market research reports, supporting clients' market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.

Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.

Browse Blog at http://2014marketresearch.blogspot.com/

Contact:
Sheela AK
State Tower
90 State Street,
Suite 700, Albany
NY 12207, United States
Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz